Concerns over potential short term adverse events (e.g. angioedema, hypotension) |
|
|
|
|
Cost of therapy/coverage challenges |
|
|
|
|
Lack of evidence regarding long-term adverse events |
|
|
|
|
Patient unwillingness to switch therapies |
|
|
|
|
Uncertainty regarding appropriate dosing/dose titration |
|
|
|
|
Uncertainty regarding efficacy data |
|
|
|
|
Uncertainty regarding who is likely to benefit |
|
|
|
|